Blood Test for Ovarian Cancer
(SOARA Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This study is designed to evaluate the safety, specificity, and downstream diagnostic burden of the Evident™ Ovarian Cancer Screening Test in average-risk postmenopausal women. Participants will provide a blood sample for screening and will be followed for approximately 12 months to assess test safety, specificity, downstream diagnostic procedures, and ovarian cancer outcomes.
Are You a Good Fit for This Trial?
This trial is for postmenopausal women who are considered to have an average risk of developing ovarian cancer. Participants should not have any known high-risk factors or a history of ovarian cancer.Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Trial Overview
The study is testing the safety and accuracy of the Evident™ blood test for detecting ovarian cancer in average-risk postmenopausal women. Participants give a blood sample and are monitored for about one year.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Postmenopausal women aged 50 years or older with no known current ovarian cancer, other active malignancy, or established ovarian cancer risk factors. The study will aim to enroll a diverse population generally representative of the US population with respect to race and ethnicity.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Mercy BioAnalytics, Inc.
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.